Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain - PubMed (original) (raw)
Review
. 2005 Oct;21(10):1617-29.
doi: 10.1185/030079905X65349.
Affiliations
- PMID: 16238902
- DOI: 10.1185/030079905X65349
Review
Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain
Joshua A Ray et al. Curr Med Res Opin. 2005 Oct.
Abstract
Objectives: To provide a comprehensive source document on previously published cost data for diabetic complications in Australia, Canada, France, Germany, Italy and Spain for use in a peer-reviewed, validated diabetes model.
Methods: A search for published cost of diabetes complications data was performed in peer-reviewed journals listed in PubMed and health economic conference proceedings from 1994 to March 2005. Where country specific data were not available, we referred to government websites and local cost experts. All costs were inflated to 2003 Euros (E). Major complication costs are presented.
Results: First year costs of non-fatal myocardial infarction varied between E19277 in Spain and E12292 in Australia. In subsequent years of treatment, this range was E1226 (France) to E203 (Australia). Angina costs were similar across all four countries: E1716 in Australia; E2218 in Canada; E2613 in France; E3342 in Germany; E2297 in Italy; and E2207 in Spain. Event costs of non-fatal stroke were higher in Canada (E23173) than in other countries (Australia E13443; France E11754; Germany E19399; Italy E6583; Spain E4638). Event costs of end-stage renal disease varied depending on the type of dialysis: in Australia (E17188-27552); Canada (E33811-58159); France (E24608-56487); Germany (E46296-68175); Italy (E43075-56717); and Spain (E28370-32706). Lower extremity amputation costs were: E18547 (Australia); E17130 (Canada); E31998 (France); E22096 (Germany); E10177 (Italy); and E14787 (Spain).
Conclusions: Overall, our search showed costs are well documented in Australia, Canada, France and Germany, but revealed a paucity of data for Spain and Italy. Spanish costs, collected by contacting local experts and from government reports, generally appeared to be lower for treating cardiovascular complications than in other countries. Italian costs reported in the literature were primarily hospitalization costs derived from diagnosis-related groups, and therefore likely to misrepresent the cost of specific complications. Additional research is required to document complication costs in Spain and Italy. Australian and German values were collected primarily by referring to diagnostic related group (DRG) tariffs and, as a result, there may be a need for future economic evaluations measuring the accuracy of the costs and resource utilization in the reported values. These cost data are essential to create models of diabetes that are able to accurately simulate the cumulative costs associated with the progression of the disease and its complications.
Similar articles
- Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL, Willis WD, Foos V. Tunis SL, et al. Curr Med Res Opin. 2010 Jan;26(1):163-75. doi: 10.1185/03007990903429765. Curr Med Res Opin. 2010. PMID: 19919377 - Acute coronary syndromes in Europe: 1-year costs and outcomes.
Taylor MJ, Scuffham PA, McCollam PL, Newby DE. Taylor MJ, et al. Curr Med Res Opin. 2007 Mar;23(3):495-503. doi: 10.1185/030079906X167462. Curr Med Res Opin. 2007. PMID: 17355731 - Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4).
Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, Heinemann L, Scherbaum WA, Kolb H. Martin S, et al. Exp Clin Endocrinol Diabetes. 2007 Sep;115(8):495-501. doi: 10.1055/s-2007-981470. Exp Clin Endocrinol Diabetes. 2007. PMID: 17853332 - The economic burden of prostate cancer.
Roehrborn CG, Black LK. Roehrborn CG, et al. BJU Int. 2011 Sep;108(6):806-13. doi: 10.1111/j.1464-410X.2011.10365.x. BJU Int. 2011. PMID: 21884356 Review. - Diabetes in Canada: direct medical costs of major macrovascular complications.
O'Brien JA, Caro I, Getsios D, Caro JJ. O'Brien JA, et al. Value Health. 2001 May-Jun;4(3):258-65. doi: 10.1046/j.1524-4733.2001.43017.x. Value Health. 2001. PMID: 11705187 Review.
Cited by
- Infrared Thermography Compared to Standard Care in the Prevention and Care of Diabetic Foot: A Cost Analysis Utilizing Real-World Data and an Expert Panel.
Kurkela O, Lahtela J, Arffman M, Forma L. Kurkela O, et al. Clinicoecon Outcomes Res. 2023 Feb 22;15:111-123. doi: 10.2147/CEOR.S396137. eCollection 2023. Clinicoecon Outcomes Res. 2023. PMID: 36855751 Free PMC article. - The price of neonatal intensive care outcomes - in-hospital costs of morbidities related to preterm birth.
Rolnitsky A, Unger S, Urbach D, Bell CM. Rolnitsky A, et al. Front Pediatr. 2023 Feb 7;11:1068367. doi: 10.3389/fped.2023.1068367. eCollection 2023. Front Pediatr. 2023. PMID: 36824649 Free PMC article. - The importance of inflammation control for the treatment of chronic diabetic wounds.
Worsley AL, Lui DH, Ntow-Boahene W, Song W, Good L, Tsui J. Worsley AL, et al. Int Wound J. 2023 Aug;20(6):2346-2359. doi: 10.1111/iwj.14048. Epub 2022 Dec 23. Int Wound J. 2023. PMID: 36564054 Free PMC article. Review. - Medical Costs Associated With Diabetes Complications in Medicare Beneficiaries Aged 65 Years or Older With Type 1 Diabetes.
Wang Y, Zhang P, Shao H, Andes LJ, Imperatore G. Wang Y, et al. Diabetes Care. 2023 Jan 1;46(1):149-155. doi: 10.2337/dc21-2538. Diabetes Care. 2023. PMID: 36399714 Free PMC article. - Medical Costs Associated With Diabetes Complications in Medicare Beneficiaries Aged 65 Years or Older With Type 2 Diabetes.
Wang Y, Zhang P, Shao H, Andes LJ, Imperatore G. Wang Y, et al. Diabetes Care. 2022 Nov 1;45(11):2570-2576. doi: 10.2337/dc21-2151. Diabetes Care. 2022. PMID: 36102675 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical